Yes. But the other explanation maybe in the health condition of the cohorts used by the doctors in Australia. I don't know how the system works but with a new product I would think the options would be put to the patients. Perhaps the sicker patients took up the offer resulting in the slightly higher adverse events.
Either way I suppose you have to know. But I don't understand why training/documentation would be superior overseas than in Australia. What more does the company need to do better here than overseas?
No Calcification, page-58
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.97 |
Change
-0.235(1.29%) |
Mkt cap ! $345.3M | |||
| Open | High | Low | Value | Volume |
| $18.09 | $18.09 | $17.88 | $1.182K | 66 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 60 | $17.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.05 | 554 | 1 |
View Market Depth
| Last trade - 14.30pm 10/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |